{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:00Z","timestamp":1786650000787,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"\n Background:<\/jats:title>\n High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) is the treatment of choice for patients with relapsed and refractory (RR) lymphoma. We analyzed toxicity and long-term outcome with lomustine, cytarabine, cyclophosphamide, etoposide (LACE) conditioning in patients with primary refractory or relapsed lymphoma undergoing autologous transplant.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n One-hundred patients with primary refractory (23), chemotherapy sensitive relapse (74) or RR (3) Hodgkin lymphoma (HL - 70 patients), and non-HL (NHL - 30 patients) underwent HSCT with LACE (lomustine 200 mg\/m\n 2<\/jats:sup>\n day-7, etoposide 1000 mg\/m\n 2<\/jats:sup>\n day-7, cytarabine 2000 mg\/m\n 2<\/jats:sup>\n day-6 to day-5, and cyclophosphamide 1800 mg\/m\n 2<\/jats:sup>\n day-4 to day-2) conditioning between November 2007 and December 2013. At transplant, 68 patients were in complete remission (CR), 29 in partial remission, 2 had stable disease, and 1 had progressive disease. Patients were followed up for development of transplant-related toxicities and long-term survival outcome.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The incidence of grades 3\u20134 oral mucositis and grades 3\u20134 diarrhea was 8% and 4%, respectively. Median days to myeloid and platelet engraftment were 10 and 13. Transplant-related mortality was 7%. At median follow-up of 3 years, probability of overall survival (OS) and progression-free survival (PFS) at 3 years was 70% and 58% in entire cohort, 78% and 62% in HL and 51% and 46% in NHL subgroup, respectively. International Prognostic Score (IPS) >2 at relapse prognosticated for poor OS (\n P<\/jats:italic>\n = 0.002) and PFS (\n P<\/jats:italic>\n < 0.001) in HL subgroup. Positron emission tomography positivity pretransplant (HL subgroup) and at day + 100 (NHL subgroup) predicted for poor survival.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n We conclude that LACE is effective and well-tolerated conditioning regimen. IPS at relapse is the most important prognostic factor in HL transplant.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0973-1482.181183","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:03:38Z","timestamp":1531991018000},"page":"926-933","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Lomustine, cytarabine, cyclophosphamide, etoposide \u2013 An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors"],"prefix":"10.4103","volume":"14","author":[{"given":"Alok","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Bone Marrow Transplant Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Gokarn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bone Marrow Transplant Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepan","family":"Rajamanickam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bone Marrow Transplant Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bone Marrow Transplant Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thippeswamy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bone Marrow Transplant Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bone Marrow Transplant Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bone Marrow Transplant Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Kannan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bone Marrow Transplant Unit, ACTREC, Tata Memorial Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,9,7]]},"reference":[{"key":"R1-20260109","first-page":"3562","article-title":"The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group","volume":"92","author":"Blay","year":"1998","journal-title":"Blood"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","article-title":"Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espa\u00f1ol de Linfomas\/Transplante Aut\u00f3logo de M\u00e9dula Osea Spanish Cooperative Group","volume":"19","author":"Sureda","year":"2001","journal-title":"J Clin Oncol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/annonc\/mdh304","article-title":"Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: A study of 341 patients","volume":"15","author":"Czyz","year":"2004","journal-title":"Ann Oncol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1200\/JCO.1993.11.10.1846","article-title":"High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma","volume":"11","author":"Vose","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4 Suppl 4","key":"R9-20260109","first-page":"50","article-title":"Comparison of preparative transplantation regimens using carmustine\/etoposide\/cisplatin or busulfan\/etoposide\/cyclophosphamide in lymphoid malignancies","volume":"20","author":"Crilley","year":"1993","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"R10-20260109","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/annonc\/9.suppl_1.S15","article-title":"Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma","volume":"9","author":"Mounier","year":"1998","journal-title":"Ann Oncol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1702795","article-title":"Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: The role of preparative regimens","volume":"27","author":"Salar","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R13-20260109","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/annonc\/8.suppl_1.S63","article-title":"Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials","volume":"8","author":"Linch","year":"1997","journal-title":"Ann Oncol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1200\/JCO.1993.11.6.1085","article-title":"Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide","volume":"11","author":"Wheeler","year":"1993","journal-title":"J Clin Oncol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.bmt.1705544","article-title":"LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: Treatment outcome and risk factor analysis in 67 patients from a single centre","volume":"39","author":"Perz","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.956","article-title":"LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: Treatment outcome and risk factor analysis from a single centre","volume":"29","author":"Pavlu","year":"2011","journal-title":"Hematol Oncol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12032-013-0611-y","article-title":"Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: A single-center experience","volume":"30","author":"Czyz","year":"2013","journal-title":"Med Oncol"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdf228","article-title":"The international prognostic factors project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation","volume":"13","author":"Bierman","year":"2002","journal-title":"Ann Oncol"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.22714","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2014","article-title":"High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: A reappraisal of prognostic factors","volume":"31","author":"Cocorocchio","year":"2013","journal-title":"Hematol Oncol"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","article-title":"BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: Comparative analysis of efficacy and toxicity","volume":"87","author":"Jo","year":"2008","journal-title":"Ann Hematol"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"S2023","DOI":"10.1182\/blood.V118.21.2023.2023","article-title":"Comparison of toxicity and outcomes of BCNU-containing conditioning regimens vs LACE in lymphoma transplants: A retrospective multicenter analysis","volume":"118","author":"Khattry","year":"2011","journal-title":"Blood"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2275::AID-CNCR25>3.0.CO;2-Q","article-title":"The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies","volume":"82","author":"Ruescher","year":"1998","journal-title":"Cancer"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bmt.1703694","article-title":"A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation","volume":"30","author":"Bolwell","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/1042819031000083028","article-title":"BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy","volume":"44","author":"Jantunen","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","article-title":"Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin's lymphoma responding to prior salvage therapy","volume":"97","author":"Devillier","year":"2012","journal-title":"Haematologica"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201814050-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:56Z","timestamp":1786647656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201814050-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.181183","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}